FLGT combines a historical earnings-beat catalyst with quality below the engine's minimum floor, a price already past target causing a negative asymmetry gate failure, falling analyst estimates, and a death-cross recovery attempt undercut by overbought technicals and elevated short/options positioning.
Thesis pillars
- Elevated Short Interest And Options Risk→Stable
- Quality Below Minimum Floor→Stable
- Target Reached Negative Asymmetry→Stable
- +2 more pillars — see the Why tab for full reasoning
Fulgent Genetics, Inc. (FLGT) Stock Analysis
Recovery setup · Catalyst-Driven edge
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $20.00: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 15%; Elevated put/call ratio: 4.83; Below-average business quality.
Fulgent Genetics operates a laboratory services business providing anatomic pathology, precision diagnostics, next-generation sequencing, and BioPharma testing services, alongside Fulgent Pharma, a therapeutic development unit advancing nanoencapsulated cancer drug candidates... Read more
Sell if holding. Engine safety override at $20.00: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 15%; Elevated put/call ratio: 4.83; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 77. Score 4.5/10, moderate confidence.
Passes 6/9 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 25d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About Fulgent Genetics, Inc.
About Fulgent Genetics, Inc.
One customer accounted for $70.8 million, or 22%, of Fulgent Genetics' total revenue in 2025, up from $62.6 million, also 22%, in 2024, underscoring the concentration risk embedded in the company's laboratory testing business. Beyond diagnostics, Fulgent Pharma is advancing two clinical-stage nanoencapsulated cancer candidates, FID-007 and FID-022, with a Phase 2 trial of FID-007 in head-and-neck squamous cell carcinoma expected to read out in the second half of 2027.
Laboratory customers are billed under three payor categories -- insurance, institutional accounts such as hospitals and other laboratories, and direct patient pay -- with institutional customers typically responsible for payment. The company depends on Illumina as the sole supplier of the next-generation sequencers and reagents used in its genetic tests and as sole provider of related maintenance, alongside single-source relationships with Roche, Leica Biosystems, and Abbott Laboratories for immunohistochemistry, digital pathology, and FISH equipment. Fulgent competes against larger, better-capitalized diagnostic peers including Laboratory Corporation of America, Quest Diagnostics, Natera, Myriad Genetics, and Tempus AI. In July 2025 the company acquired the remaining equity of ANP Technologies to gain full ownership of previously licensed nanoencapsulation patents underlying FID-007 and FID-022, and it has pending acquisitions of StrataDx and certain Bako Diagnostics pathology assets to expand its laboratory footprint.
Show full overview
A litigation overhang beyond diagnostic accuracy sits in reimbursement compliance: Fulgent discloses an ongoing HRSA Audit and unspecified Civil Investigative Demands that could result in material refunds or settlements tied to how the company submitted claims for its tests and testing services. Separately, the customer responsible for 22% of 2025 revenue began reducing test orders in the fourth quarter of 2025 as it shifts some testing in-house, a transition Fulgent expects will reduce revenue from that account through at least the second quarter of 2026.
See also: Healthcare · Diagnostics & Research
From Fulgent Genetics, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- LOWCustomerone large customer22%10-K Item 1: 'one of our customers contributed $70.8 million or 22% of our total revenue in 2025, and $62.6 million or 22% of our total revenue in 2024'
- HIGHSupplierIllumina10-K Item 1: 'we rely on Illumina Inc., or Illumina, as the sole supplier of the next generation sequencers and associated reagents we use to perform our genetic tests'
Material Events(8-K, last 90d)
- 2026-05-14Item 5.02LOWAt the 2026 Annual Meeting on May 14, 2026, stockholders approved a new 2026 Equity Incentive Plan authorizing 2,000,000 new shares (plus up to 1,500,000 more from forfeited prior-plan awards), replacing the 2016 Omnibus Incentive Plan.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Revenue shrinking — -3.2% YoY. Growth thesis broken unless recovery story develops.static
Unprofitable operations — net margin -23.0%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $20.00: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 15%; Elevated put/call ratio: 4.83; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 77. Prior stop was $20.07. Score 4.5/10, moderate confidence.
Take-profit target: $21.07 (-1.5% upside). Prior stop was $20.07. Stop-loss: $20.07.
Concentration risk — Supplier: Illumina; Target reached (-26.5% upside); Quality below floor (2.0 < 4.0).
Fulgent Genetics, Inc. trades at a P/E of N/A (forward -13.6). TrendMatrix value score: 9.1/10. Verdict: Sell.
6 analysts cover FLGT with a consensus score of 2.2/5. Average price target: $19.
What does Fulgent Genetics, Inc. do?Fulgent Genetics operates a laboratory services business providing anatomic pathology, precision diagnostics,...
Fulgent Genetics operates a laboratory services business providing anatomic pathology, precision diagnostics, next-generation sequencing, and BioPharma testing services, alongside Fulgent Pharma, a therapeutic development unit advancing nanoencapsulated cancer drug candidates FID-007 and FID-022. Laboratory customers pay through insurance, institutional, or direct patient-pay channels, and one aggregated customer contributed $70.8 million, or 22% of total revenue, in 2025.